J.H. OORTWEG 21, LEIDEN, P7
Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks
Topline Data
Unaudited Condensed Consolidated Interim Financial Statements
Annual Report for the Fiscal Year Ended December 31, 2025
Unaudited Condensed Consolidated Interim Financial Statements For the Three Months Ended March 31, 2026
Enters Into Underwriting Agreement with Morgan Stanley & Co. LLC and Leerink Partners LLC
Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Pioneering Science for Patient Choice Presentation January 2026
Annual and Transition Report of Foreign Private Issuers
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
No filings found
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Amended Schedule 13G - Ownership Report
Automatic Shelf Registration Statement
Submission Upload
Correspondence
Free Writing Prospectus
Automatic Shelf Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Amended Notice of Proposed Sale of Securities